<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969939</url>
  </required_header>
  <id_info>
    <org_study_id>NN9775-4708</org_study_id>
    <secondary_id>U1111-1254-9046</secondary_id>
    <nct_id>NCT04969939</nct_id>
  </id_info>
  <brief_title>A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity</brief_title>
  <official_title>Investigation of Efficacy and Safety of NNC0165-1875 as add-on to Semaglutide for Weight Management in Subjects With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is looking at a new medicine to help people lose weight. In this study participants&#xD;
      will either get semaglutide and NNC0165-1875 or semaglutide and a &quot;dummy&quot; medicine (placebo).&#xD;
      Which treatment participants get is decided by chance. Participants will get 2 injections per&#xD;
      week, on the same day. Participants will have to take the study medicine by use of a&#xD;
      pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The&#xD;
      study doctor or staff will show participants how. The study will last for about 26 weeks.&#xD;
      Participants will have 17 visits at the clinic with the study doctor. At 4 of the clinic&#xD;
      visits participants cannot eat and drink (water is allowed until 2 hours prior to the visit)&#xD;
      for 8 hours before the visit.Women: Women cannot take part if pregnant, breast-feeding or&#xD;
      plan to become pregnant during the study period. Women who are able to become pregnant can&#xD;
      participate if they agree to use contraception during the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">January 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1: is a 16-week study were one group of participants will receive two doses of NNC0165-1875 a week, in combination with one injection dose of semaglutide a week. The other group will receive a placebo.&#xD;
Part 2: is a 40-week study were one group of participants will receive one dose of NNC0165 a week, in combination with one injection dose of semaglutide a week. The other group will receive a placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From time of dosing (day 1) to follow-up (week 24)</time_frame>
    <description>Number of events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change in body weight</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in body weight</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in HbA1c</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>Percentage point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in fasting plasma glucose</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in fasting insulin</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>pmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in waist circumference</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Relative change in total cholesterol</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Relative change in HDL cholesterol</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Relative change in LDL cholesterol</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Relative change in VLDL cholesterol</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Relative change in Triglycerides</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Relative change in Free fatty acids</measure>
    <time_frame>From randomisation (week 24) to end of treatment (week 40)</time_frame>
    <description>ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline at (week 0) to end of trial (week 48)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of serious treatment emergent adverse events (SAEs)</measure>
    <time_frame>From baseline at (week 0) to end of trial (week 48)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Semaglutide 2.4 mg and NNC0165-1875 2.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo as an add on to semaglutide 2.4 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 2.4 mg and NNC0165-1875 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo as an add on to semaglutide 2.4 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4 mg and NNC0165-1875 2.0 mg</intervention_name>
    <description>NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.</description>
    <arm_group_label>Semaglutide 2.4 mg and NNC0165-1875 2.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4 mg and placebo 2.0 mg</intervention_name>
    <description>NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.</description>
    <arm_group_label>Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4 mg and NNC0165-1875 1.0 mg</intervention_name>
    <description>NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.</description>
    <arm_group_label>Semaglutide 2.4 mg and NNC0165-1875 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4 mg and placebo 1.0 mg</intervention_name>
    <description>NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.</description>
    <arm_group_label>Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial.&#xD;
&#xD;
          -  Male or female, age above or equal to 18 years at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          -  BMI 30.0 - 45.0 kg/m^2 (both inclusive) at the screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HbA1c greater than or equal to 48 mmol/mol (6.5%) as measured by a central laboratory&#xD;
             at screening.&#xD;
&#xD;
               -  History of type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
               -  Treatment with glucose-lowering agent(s) within 90 days before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-2477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

